98%
921
2 minutes
20
Atherosclerosis still represents a major driver of cardiovascular diseases worldwide. Together with accumulation of lipids in the plaque, inflammation is recognized as one of the key players in the formation and development of atherosclerotic plaque. Systemic anti-inflammatory treatments are successful in reducing the disease burden, but are correlated with severe side effects, underlining the need for targeted formulations. In this work, curcumin is chosen as the anti-inflammatory payload model and further loaded in lignin-based nanoparticles (NPs). The NPs are then coated with a tannic acid (TA)- Fe (III) complex and further cloaked with fragments derived from platelet cell membrane, yielding NPs with homogenous size. The two coatings increase the interaction between the NPs and cells, both endothelial and macrophages, in steady state or inflamed status. Furthermore, NPs are cytocompatible toward endothelial, smooth muscle and immune cells, while not inducing immune activation. The anti-inflammatory efficacy is demonstrated in endothelial cells by real-time quantitative polymerase chain reaction and ELISA assay where curcumin-loaded NPs decrease the expression of Nf-κb, TGF-β1, IL-6, and IL-1β in lipopolysaccharide-inflamed cells. Overall, due to the increase in the cell-NP interactions and the anti-inflammatory efficacy, these NPs represent potential candidates for the targeted anti-inflammatory treatment of atherosclerosis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11468963 | PMC |
http://dx.doi.org/10.1002/adhm.202302074 | DOI Listing |
Obesity (Silver Spring)
September 2025
Eli Lilly and Company, Indianapolis, Indiana, USA.
Objective: SURMOUNT-MAINTAIN aims to evaluate the efficacy and safety of reducing the tirzepatide dose and/or continuing the maximum tolerated dose (MTD) versus placebo in maintaining body weight (BW) reduction achieved with tirzepatide MTD.
Methods: This Phase 3b, multicenter, randomized, parallel-arm, double-blinded, placebo-controlled, 52-week clinical trial is in progress comparing treatment with once weekly tirzepatide (5 mg and/or MTD of 15 mg or 10 mg) versus placebo in achieving BW reduction maintenance from the initial 60-week open-label weight-loss period on tirzepatide MTD, in adults with obesity (BMI ≥ 30 kg/m or ≥ 27 kg/m with ≥ 1 obesity-related comorbidity, excluding type 2 diabetes). The primary endpoint is percent maintenance of BW reduction achieved during the weight-loss period at Week 112 among those who reached a BW plateau (i.
Eur J Prev Cardiol
September 2025
Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
J Am Heart Assoc
September 2025
Background: Cardiac issues following radiotherapy are increasingly prevalent among patients with thoracic cancer and coronary disease. However, the mechanisms underlying radiotherapy-induced plaque instability and changes in plaque characteristics on imaging remain unclear. This study used single-cell RNA sequencing to identify key features of vulnerable plaques following radiotherapy.
View Article and Find Full Text PDFJ Cell Mol Med
September 2025
Department of Diagnostics, Hunan University of Medicine, Huaihua, Hunan, China.
The underlying mechanisms in atherosclerotic vascular diseases are not entirely clear, posing a challenging hurdle to treatment. Inflammation is a root cause of atherosclerosis (AS); therefore, anti-inflammatory agents have potential for its management. Sweroside, possessing anti-inflammatory properties, emerges as a potential agent to impede AS progression.
View Article and Find Full Text PDFJ Ethnopharmacol
September 2025
Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China. Electronic address:
Ethnopharmacological Relevance: Naoxintong, a Chinese patent medicine, may serve as an adjunctive therapy for the secondary prevention of ischemic stroke.
Aim Of The Study: To assess the effectiveness and safety of Naoxintong in preventing recurrent ischemic stroke and to review its preclinical evidence.
Materials And Methods: A search of electronic databases and registries was performed to locate relevant randomized controlled trials (RCTs) on Naoxintong for preventing ischemic stroke recurrence and animal studies exploring its mechanisms in atherosclerosis improvement.